Initial Statement of Beneficial Ownership (3)
June 06 2017 - 6:18PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Utter Christine Marie
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
6/2/2017
|
3. Issuer Name
and
Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [PTCT]
|
(Last)
(First)
(Middle)
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Principal Financial Officer /
|
(Street)
SOUTH PLAINFIELD, NJ 07080
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Common Stock
|
5297
(1)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right To Buy)
|
(2)
|
4/27/2021
|
Common Stock
|
74.0
|
$490.8
|
D
|
|
Stock Option (Right To Buy)
|
(2)
|
1/10/2022
|
Common Stock
|
21.0
|
$218.4
|
D
|
|
Stock Option (Right To Buy)
|
(2)
|
5/15/2023
|
Common Stock
|
1150.0
|
$10.85
|
D
|
|
Stock Option (Right To Buy)
|
(3)
|
1/28/2024
|
Common Stock
|
3369.0
|
$27.05
|
D
|
|
Stock Option (Right To Buy)
|
(4)
|
9/23/2024
|
Common Stock
|
4688.0
|
$40.45
|
D
|
|
Stock Option (Right To Buy)
|
(5)
|
1/2/2025
|
Common Stock
|
17800.0
|
$51.0
|
D
|
|
Stock Option (Right To Buy)
|
(6)
|
1/3/2026
|
Common Stock
|
11000.0
|
$30.86
|
D
|
|
Stock Option (Right To Buy)
|
(7)
|
1/2/2027
|
Common Stock
|
12600.0
|
$11.23
|
D
|
|
Explanation of Responses:
|
(1)
|
Includes 3,900 shares of Restricted Stock Units awarded to the Reporting Person, which vests in four equal annual installments over four years, commencing on January 3, 2018.
|
(2)
|
Currently exercisable.
|
(3)
|
This option was granted on January 28, 2014 and vests over four years, with 25% of the shares underlying the option vested on January 28, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 28, 2015.
|
(4)
|
This option was granted on September 23, 2014 and vests over four years, with 25% of the shares underlying the option vested on September 23, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on December 23, 2015.
|
(5)
|
This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on January 2, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2016.
|
(6)
|
This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
|
(7)
|
This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Utter Christine Marie
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080
|
|
|
Principal Financial Officer
|
|
Signatures
|
Avraham S. Adler, attorney-in-fact
|
|
6/6/2017
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
PTC Therapeutics (NASDAQ:PTCT)
Historical Stock Chart
From Apr 2023 to Apr 2024